Thermo Fisher Scientific (NYSE:TMO) Coverage Initiated at DZ Bank

Equities researchers at DZ Bank started coverage on shares of Thermo Fisher Scientific (NYSE:TMO) in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The firm set a “buy” rating and a $610.00 price target on the medical research company’s stock. DZ Bank’s price target suggests a potential upside of 28.74% from the company’s previous close.

Other analysts have also issued research reports about the stock. KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 target price for the company in a research note on Sunday, December 7th. Stifel Nicolaus lifted their price target on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a “buy” rating in a report on Friday, January 9th. Wells Fargo & Company set a $683.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. UBS Group restated a “neutral” rating and issued a $615.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Finally, Barclays increased their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $632.50.

Thermo Fisher Scientific Stock Down 3.1%

Shares of Thermo Fisher Scientific stock opened at $473.83 on Friday. The business has a 50-day moving average price of $530.10 and a 200 day moving average price of $547.79. Thermo Fisher Scientific has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The firm has a market cap of $176.02 billion, a P/E ratio of 26.71, a P/E/G ratio of 2.73 and a beta of 0.96. The company has a quick ratio of 1.53, a current ratio of 1.89 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping the consensus estimate of $6.45 by $0.12. The company had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The business’s revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the firm earned $6.10 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific will post 23.28 earnings per share for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the sale, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This trade represents a 1.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The SEC filing for this sale provides additional information. 0.33% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Rockefeller Capital Management L.P. increased its stake in Thermo Fisher Scientific by 24.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 422,980 shares of the medical research company’s stock valued at $245,098,000 after buying an additional 84,122 shares during the period. Bank of New Hampshire boosted its holdings in shares of Thermo Fisher Scientific by 51.5% in the fourth quarter. Bank of New Hampshire now owns 1,904 shares of the medical research company’s stock valued at $1,103,000 after acquiring an additional 647 shares in the last quarter. World Investment Advisors increased its stake in shares of Thermo Fisher Scientific by 1.8% during the fourth quarter. World Investment Advisors now owns 17,231 shares of the medical research company’s stock valued at $9,985,000 after acquiring an additional 297 shares during the period. Farmers National Bank lifted its position in Thermo Fisher Scientific by 43.4% in the fourth quarter. Farmers National Bank now owns 2,401 shares of the medical research company’s stock worth $1,391,000 after purchasing an additional 727 shares during the period. Finally, Nalls Sherbakoff Group LLC bought a new position in Thermo Fisher Scientific during the 4th quarter valued at $72,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.